Clinical failures of linezolid and implications for the clinical microbiology laboratory

Emerging Infectious Diseases

Volumn 8, Issue 12, 2002, Pages 1519-1520

  Potoski, Brian A ^a,b   Mangino, Julie E ^a   Goff, Debra A ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b Falk Medical Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B LIPID COMPLEX; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN; FLUCONAZOLE; GENTAMICIN; IMIPENEM; LINEZOLID; NAFCILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINUPRISTIN; TOBRAMYCIN; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIUM CULTURE; CASE REPORT; CLINICAL FEATURE; DRUG INDICATION; ENTEROCOCCUS FAECIUM; FEMALE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NOTE; REFRACTORY ANEMIA; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036913851     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0812.020139     Document Type: Note

References (10)

1. Linezolid (Zyvox) Package Insert. Peapack (NJ): Pharmacia & Upjohn Company; 2000.
2. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Informational Supplement. Document M100-S12. Vol 22. No 1. Wayne (PA): The Committee; 2002.
3. Melzer M, Goldsmith D, Gransden W. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias. Clin Infect Dis 2000;31:208-9.
4. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357:1179.
5. Linden PK, Pasculle AW, Manez R, Kramer DJ, Fung JJ, Pinna AD, et al. Difference in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996;22:663-70.
6. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 2000;30:146-51.
7. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55.
8. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlick SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998;244:379-86.
9. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8.
10. Herrero IA, Issa NC, Patel. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002;346:867-9.